Anna Protopapas - Jun 3, 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc (DRNA)

Role
Director
Signature
/s/ Douglas W. Pagan, attorney-in-fact
Stock symbol
DRNA
Transactions as of
Jun 3, 2021
Transactions value $
$0
Form type
4
Date filed
6/7/2021, 09:34 PM
Next filing
Jul 19, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRNA Common Stock Options Exercise +3.33K 3.33K Jun 3, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRNA Restricted Stock Units Options Exercise $0 -3.33K -100% $0.00* 0 Jun 3, 2021 Common Stock 3.33K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Anna Protopapas is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
F2 Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021.